Nivolumab and relatlimab

Entry

D12334            Mixture   Drug

Name

Nivolumab and relatlimab;
Nivolumab and relatlimab-rmbw;
Opdualag (TN)

Product

OPDUALAG (E.R. Squibb & Sons)

Component

Nivolumab [DR:D10316], Relatlimab [DR:D11350]

Class

Antineoplastic
DG02938 Immune checkpoint inhibitor

Remark

Product:

D12334<US>

Efficacy

Antineoplastic, Immune checkpoint inhibitor

Disease

Melanoma [DS:H00038]

Brite

Drug groups [BR:br08330]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12334  Nivolumab and relatlimab
Drug classes [BR:br08332]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12334  Nivolumab and relatlimab
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D12334